ArticleFrontiers in endocrinology2025
Prediction of malignancy risk in Bethesda III nodules: development and validation of multiple machine learning models.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Complete pathologic necrosis of a thyroid neoplasm following pressure-enabled thyroid artery embolization.JCEM case reports · 2026Article
- Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features.Frontiers in oncology · 2026Article
- An interpretable machine learning-based approach: development, validation, and clinical utility for distant metastasis prediction in PTC.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a machine learning (ML)-based prediction model of Bethesda III nodules and create a nomogram based on the best model. Methods: We collected data on patients with Bethesda III nodules who were admitted between January 2020 and June 2024, including 276 Bethesda III nodules from 7371 patients who underwent ultrasound-guided fine needle aspiration (US-FNA). Clinical, ultrasonographic, cytological, laboratory, and molecular data were collected and randomly split into training and validation cohorts at a ratio of 7: 3. Six feature selection methods and ML algorithms-Logistic Regression (LR), Decision Tree (DT), Random Forest (RF), Extreme Gradient Boosting (XGB), Support Vector Machine (SVM), and K-Nearest Neighbors (KNN)-were evaluated. A nomogram was then created based on the best-performing model. Results: The study cohort included 276 Bethesda III nodules with a final malignancy rate of 65.2% (180/276). LR exhibited the highest area under the receiver operating characteristic (ROC) curve (AUC: 0.823) in cross-validation of the validation set. Additionally, the calibration curves and Decision Curve Analysis (DCA) results were also favorable. The model included BRAF, composition, shape, orientation, and the thyroid imaging reporting and data system (TI-RADS). The nomogram exhibited robust discrimination (AUC: 0.846 in the validation set), calibration, and clinical applicability across the two datasets after 500 bootstraps. Conclusion: Among the six ML algorithms, the LR algorithm demonstrated the best performance. A nomogram was developed to predict the malignancy risk in Bethesda III nodules. This nomogram may serve as a valuable tool to reduce diagnostic uncertainty and provide personalized risk stratification for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.